Skyhawk Therapeutics is developing small molecules that modify RNA expression to revolutionize disease treatment. Many diseases are underpinned by changes in RNA expression - Skyhawk is using their unique platform to accelerate the creation of RNA targeting small molecules across a range of fields including neurology, oncology and autoimmune diseases. Skyhawk’s lead program, SKY-0515, is a novel RNA-targeting small molecule that is in clinical trials for Huntington’s disease. SKY-0515 works by reducing the levels of the disease-causing mRNA encoding huntingtin and has shown positive results in a Phase 1 study.

Skyhawk Therapeutics

Founded: 2018
Location: Waltham, MA
Employee range: 50 - 200
Clinical stage: Clin0
Therapy area: Neurodegenerative condition
Drug types: NEU, ONC, MUS, IMM
Lead product: Undisclosed
Funding: $133M Sep 2021; $40M A Jul 2018; $8M seed Jan 2018

Drug notes:

About:

Jobs: